Evidence map›Paper›PMID 27080183›Full record

ReviewBioorganic & medicinal chemistry letters2016

Repurposing strategies for tropical disease drug discovery.

Dana M Klug, Michael H Gelb, Michael P Pollastri

Abstract readReview
In one paragraph

Review in Bioorganic & medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Drug resistance in animal trypanosomiases: Epidemiology, mechanisms and control strategies.International journal for parasitology. Drugs and drug resistance · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Frontiers in cellular and infection microbiology · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dana M KlugNortheastern University, Department of Chemistry & Chemical Biology, 360 Huntington Avenue, Boston, MA 02115, USA.
Michael H GelbUniversity of Washington, Department of Chemistry, Campus Box 351700, Seattle, WA 98195-1700, USA.
Michael P PollastriNortheastern University, Department of Chemistry & Chemical Biology, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address: m.pollastri@neu.edu.

Funding

Repurposing human kinase inhibitor chemotypes for Neglected Tropical DiseasesR01AI114685 · NIAID · NORTHEASTERN UNIVERSITY · PI FERRINS, LORI · 2015 to 2025
$4.6M
Lead Optimization of Lapatinib Analogs for Human African TrypanosomiasisR56AI099476 · NIAID · UNIVERSITY OF GEORGIA · PI MENSA-WILMOT, KOJO A., POLLASTRI, MICHAEL P · 2014 to 2014
$672k
NIAID NIH HHS R01 AI114685NIAID NIH HHS R56 AI099476
6 · The paper itself

Abstract

Neglected tropical diseases (NTDs) and other diseases of the developing world, such as malaria, attract research investments that are disproportionately low compared to their impact on human health worldwide. Therefore, pragmatic methods for launching new drug discovery programs have emerged that repurpose existing chemical matter as new drugs or new starting points for optimization. In this Digest we describe applications of different repurposing approaches for NTDs, and provide a means by which these approaches may be differentiated from each other. These include drug repurposing, target repurposing, target class repurposing, and lead repurposing.

Indexed as

Drug DiscoveryHumansMolecular StructureNeglected DiseasesDrug repositioningDrug repurposingLead repurposingNeglected tropical diseasePiggy-back drug discoveryTarget class repurposingTarget repurposingTropical disease

Identifiers

PMID27080183
PMCPMC4853260

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.